
ACE-031
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
ACE-031 is a soluble decoy receptor built as a fusion of the activin receptor type IIB (ActRIIB) with an antibody Fc region. It acts as a molecular "trap," binding myostatin and related ligands before they can reach their real receptors.
| Test | Result | Status |
|---|---|---|
| Purity | 99.4% | Passed ✓ |
Research Information
ACE-031 is studied for its inhibition of the ActRIIB pathway and the resulting influence on muscle-cell growth in models of muscle biology. By intercepting multiple negative regulators of muscle mass at the ligand level, it offers a receptor-decoy approach distinct from direct myostatin antibodies. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
ACE-031 Research & Studies
What is ACE-031?
ACE-031 is a soluble decoy receptor constructed as a fusion protein linking the extracellular domain of activin receptor type IIB (ActRIIB) to an immunoglobulin Fc region. In laboratory research it functions as a ligand trap that sequesters myostatin and related TGF-beta superfamily members before they engage endogenous receptors. The molecule is examined exclusively in in-vitro and controlled model systems of muscle biology to map ligand-receptor interactions. It is supplied strictly for research use and is not intended for any form of administration.
Mechanism of Action
ACE-031 binds circulating and locally produced ligands such as myostatin, activin A, and GDF11 with high affinity, thereby preventing their interaction with cell-surface ActRIIB. This ligand sequestration interrupts downstream Smad signaling cascades that normally restrain myoblast differentiation and muscle-fiber growth in experimental models. The multi-ligand trapping strategy distinguishes ACE-031 from single-target antibodies and allows simultaneous interrogation of several negative regulators of muscle mass within the same assay system.
Primary Areas of Research
Investigators employ ACE-031 to probe ActRIIB pathway inhibition and its consequences for muscle-cell hypertrophy, satellite-cell activation, and myogenic gene expression in cell-culture and tissue-explant models. Studies also explore how decoy-receptor interception of multiple ligands alters extracellular matrix remodeling and metabolic signaling in muscle-derived cells. Comparative work evaluates the receptor-decoy approach against other strategies that target individual ligands or intracellular kinases.
Key Research Findings
Published laboratory investigations have documented that ACE-031 effectively reduces free myostatin and related ligands in culture media, leading to measurable shifts in markers of muscle-cell growth and differentiation. Binding-affinity and ligand-selectivity profiles have been characterized, confirming simultaneous capture of several ActRIIB ligands. These findings support the utility of ACE-031 as a tool for dissecting multi-ligand regulation of muscle biology under controlled experimental conditions.
Research Handling & Considerations
ACE-031 is provided solely for in-vitro and laboratory research applications. Researchers should store the lyophilized or buffered material according to standard fusion-protein protocols and reconstitute it under aseptic conditions compatible with cell-based assays. Careful attention to buffer composition, temperature, and avoidance of repeated freeze-thaw cycles helps preserve ligand-binding activity. The compound is not for human or animal consumption or any non-research purpose.
Frequently Asked Questions
ACE-031 consists of the ligand-binding extracellular domain of ActRIIB fused to an antibody Fc region, creating a soluble decoy receptor used in research assays.
Explore Other High-Purity Peptides

Ipamorelin

CJC-1295 (No DAC)

Sermorelin
